| P50 | author | Amrinder Singh | Q87810190 |
| | Siddharth Jhunjhunwala | Q37929149 |
| P2093 | author name string | Hanudatta S Atreya | |
| | Annapoorni Rangarajan | |
| | Neha Deshpande | |
| | Nilkamal Pramanik | |
| P2860 | cites work | Evidence for a direct antitumor mechanism of action of bovine lactoferricin. | Q52548928 |
| | The biology of the opioid growth factor receptor (OGFr) | Q55954264 |
| | Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofoltate reductase | Q67594615 |
| | The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities | Q27012984 |
| | Structure, dynamics, and catalytic function of dihydrofolate reductase | Q28261353 |
| | Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles | Q28390739 |
| | A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. | Q34343581 |
| | Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. | Q34447986 |
| | Dihydrofolate reductase inhibitory peptides screened from a structured designed β-loop peptide library displayed on phage | Q35676500 |
| | Cancer treatment using peptides: current therapies and future prospects | Q36515785 |
| | Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy | Q36677915 |
| | Designing antimicrobial peptides: form follows function. | Q37968899 |
| | Expanding the organic toolbox: a guide to integrating biocatalysis in synthesis | Q37974847 |
| | Peptide targeted lipid nanoparticles for anticancer drug delivery. | Q38016810 |
| | Molecular tools for the construction of peptide-based materials. | Q38180601 |
| | Peptide therapeutics: current status and future directions | Q38275750 |
| | Functionalized polystyrene nanoparticles as a platform for studying bio-nano interactions. | Q38351713 |
| | The Current State of Peptide Drug Discovery: Back to the Future? | Q38652744 |
| | Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study. | Q39136463 |
| | Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias | Q39794414 |
| | Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype 2. | Q40373639 |
| | Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling. | Q40556150 |
| | Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux | Q40866472 |
| | Eukaryotic dihydrofolate reductase | Q40991677 |
| | Tumor resistance to antimetabolites | Q41749087 |
| | Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo | Q43547625 |
| | Treatment of advanced pancreatic cancer with opioid growth factor: phase I. | Q44344822 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3190 | |
| P577 | publication date | 2018-02-16 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer | |
| P478 | volume | 8 | |